US Pharma MarketingNew FDA leadership strikes conciliatory note on rare diseases, staff morale
Three acting FDA leaders at BIO pitch rare disease framework and 2,200-hire rebuilding plan as agency works to restore trust post-Makary. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for…
After a year of disruptions and industry consternation, a trio of current FDA leaders tried to turn over a new leaf both in the agency’s relationship with the industry it regulates and the staff that ...
Source: Endpoints News